### Table of Contents

#### Cover Figure

#### Editorials and Perspectives

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>655</td>
<td>Cure trends in acute lymphoblastic leukemia: is it time for a revised concept of cure?</td>
<td>Christian Michel Zwaan and Richard Sposto</td>
</tr>
<tr>
<td>657</td>
<td>To respond or not to respond to hydroxyurea in thalassemia: a matter of stress adaptation?</td>
<td>Antonella Ronchi and Sergio Ottolenghi</td>
</tr>
<tr>
<td>660</td>
<td>Lenalidomide in the treatment of plasma cell dyscrasia: state of the art and perspectives</td>
<td>Antonio Palumbo and Federica Cavallo</td>
</tr>
<tr>
<td>662</td>
<td>High-dose chemotherapy and autologous stem cell transplantation for secondary central nervous system lymphoma: many are called, but few are chosen</td>
<td>Jeremy S. Abramson</td>
</tr>
<tr>
<td>665</td>
<td>T315I, more or less, predicts for major molecular response: the devil is in the details!</td>
<td>Michael J. Mauro</td>
</tr>
</tbody>
</table>

#### Review Articles

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>667</td>
<td>Principles of care for the diagnosis and treatment of von Willebrand disease</td>
<td>Giancarlo Castaman, Anne Goodeve, and Jeroen Eikenboom, on behalf of the European Group on von Willebrand disease (EUVWD)</td>
</tr>
<tr>
<td>675</td>
<td>Clinical implications of the molecular genetics of chronic lymphocytic leukemia</td>
<td>Robin Foa, Ilaria Del Giudice, Anna Guarini, Davide Rossi, and Gianluca Gaidano</td>
</tr>
</tbody>
</table>

#### Original Articles and Brief Reports

- **Hematopoietic Growth Factors**
  - **686** Darbepoietin-alfa has comparable erythropoietic stimulatory effects to recombinant erythropoietin whilst preserving the bone marrow microenvironment
    - Sita R. Dewanmitta, Megan R. Russell, Harshal Nanadurkar, and Carl R. Walkey

- **Thalassemia Syndromes**
  - **691** Mosaic segmental uniparental isodisomy and progressive clonal selection: a common mechanism of late onset β-thalassemia major
    - Cornelis L. Hartevedt, Chiara Refaldi, Antonino Giambona, Claudia A. L. Ruivenkamp, Mariette J. V. Hoffer, Jeroen Pijpe, Peter De Knijff, Caterina Borgna-Pignatti, Aurelio Maggio, Maria D. Cappellini, and Piero C. Giordano

- **696** Hydroxyurea responsiveness in β-thalassemic patients is determined by the stress response adaptation of erythroid progenitors and their differentiation propensity
  - Farzin Pourfarzad, Maricke von Lindern, Azita Azarkeivan, Jun Hou, Sima Kheradmand Kia, Fatemehsadat Esteghamat, Wilfred van IJcken, Spaak Philipsen, Hossein Najmabadi, and Frank Grosveld

- **Bone Marrow Failure Syndromes**
  - **705** Elevated levels of STAT1 in Fanconi anemia group A lymphoblasts correlate with the cells’ sensitivity to DNA interstrand crosslinking drugs
    - Inés Prieto-Romón, Dámaso Sánchez-Carrera, Mónica López-Duarte, Carlos Richard, and Carlos Pipaón

- **Chronic Myeloid Leukemia**
  - **714** The quantitative level of T315I mutated BCR-ABL predicts for major molecular response to second-line nilotinib or dasatinib treatment in patients with chronic myeloid leukemia
    - Thoralf Lange, Thomas Ernst, Franz X. Gubler, Jacqueline Maier, Michael Cross, Martin C. Müller, Dietger Niederwieser, Andreas Hochhaus, and Markus Pfirrmann
Chronic Myeloproliferative Disorders

Clonal analyses reveal associations of JAK2V617F homozygosity with hematologic features, age and gender in polycythemia vera and essential thrombocythemia
Anna L. Godfrey, Edwin Chen, Francesca Pagano, Yvonne Silber, Peter J. Campbell, and Anthony R. Green

718

JAK2 p.V617F allele burden in myeloproliferative neoplasms one month after allogeneic stem cell transplantation significantly predicts outcome and risk of relapse
Thoralf Lange, Anja Edelmann, Udo Siebelts, Rainer Kralh, Claudia Nehring, Nadja Jakel, Michael Cross, Jacqueline Matz, Dietger Nieblerwieser, and Claudia Wickenhauser

722

Molecular & Cellular Basis of Leukemia & Lymphoma

Cancerous inhibitor of protein phosphatase 2A determines bortezomib-induced apoptosis in leukemia cells
Chun-Yu Liu, Chung-Wai Shiau, Hsin-Yu Kuo, Hsiang-Po Huang, Ming-Huang Chen, Cheng-Huai Tseng, and Kuen-Feng Chen

729

The role of a newly identified SET domain-containing protein, SETD3, in oncogenesis
Zhangguo Chen, Catherine T. Yan, Yali Dou, Sawannee S. Viboolsittiseri, and Jing H. Wang

739

Acute Lymphoblastic Leukemia

Survival and cure trends for European children, adolescents and young adults diagnosed with acute lymphoblastic leukemia from 1982 to 2002
Gemma Gatta, Silvia Rossi, Roberto Foschi, Amalisa Trama, Rafael Maros-Gragera, Guido Pastore, Rafael Peris-Bonet, Charles Stiller, Riccardo Capocaccia, and the EUROCASE Working Group

744

Cost-analysis of treatment of childhood acute lymphoblastic leukemia with asparaginase preparations: the impact of expensive chemotherapy
Wing H. Tong, Inge M. van der Sluis, Cathelijne J.M. Allema, Raphaëlle R.L. van Litsenburg, Gertjan J. L. Kaspers, Rob Pieters, and Carin A. Uyl-de Groot

753

Hodgkin’s Lymphoma

Development of classical Hodgkin’s lymphoma in an adult with biallelic STXB2P2 mutations
Maciej Machaczka, Monika Klimkowska, Samuel C. C. Chiang, Marie Meeth, Martha-Lena Müller, Brit Gustafsson, Jan-Inge Henter, and Yenan T. Bryceson

760

Non-Hodgkin’s Lymphomas

Prognosis of patients with primary central nervous system lymphoma after high-dose chemotherapy followed by autologous stem cell transplantation
Elisabeth Schorb, Benjamin Kasenda, Johannes Atta, Stephan Kaua, Anke Morgen, Georg Hess, Thomas Elter, Nikolas von Bubnoff, Martin Dreyling, Mark Ringhofer, Stefan W. Krause, Günter Derigs, Beate Klimm, D. Niemann, Kristina Fritsch, Jürgen Finke, and Gerald Il härhaus

765

Lymphoproliferative Disorders

The accuracy of positron emission tomography in the detection of posttransplant lymphoproliferative disorder
Daan Dierickx, Thomas Toussen, Amelie Requilé, Raf Versuren, Xavier Sagraert, Julie Morscio, Iwona Włodarska, An Herreman, Dirk Kuypers, Johan Van Cleemput, Frederik Nevens, Lieven Dupont, Anne Uyttebroeck, Jacques Piore, Christiane De Wolf-Peeters, Gregor Verhoef, Lieselot Brepoels, and Olivier Ghysens

771

Multiple Myeloma

Lenalidomide as salvage treatment for multiple myeloma relapsing after allogeneic hematopoietic stem cell transplantation: a report from the French Society of Bone Marrow and Cellular Therapy
Tereza Coman, Emmanuel Bachy, Mauricette Michellet, Gérard Socié, Madalina Uzumov, Jean Henri Bourhis, Simona Lapusan, Alain Brebion, Stéphane Vignon, Sébastien Maury, Sylvie François, Anne Huypih, Bruno Lioure, Ibrahim Yakoub-Agha, Olivier Hermine, Noël Milpied, Mohammad Molty, and Marie-Thérèse Rubio

776

Lenalidomide, melphalan, and prednisone, followed by lenalidomide maintenance, improves health-related quality of life in newly diagnosed multiple myeloma patients aged 65 years or older: results of a randomized phase III trial
Meletios A. Dimopoulos, Michel Delforge, Roman Häjek, Martin Kropp, Maria T. Petrucci, Philip Lewis, Amabel Nixon, Jingliang Zhang, Jay Mei, and Antonio Palumbo

784
Letters to the Editor

Letters are available online only at www.haematologica.org/content/98/5.toc

- Predictors of survival in thrombotic thrombocytopenic purpura
  Shruti Chaturvedi and Nirmannath Bhatia
  http://www.haematologica.org/content/98/5/e58

- TP53 mutations are frequent in adult acute lymphoblastic leukemia cases negative for recurrent fusion genes and correlate with poor response to induction therapy
  Sabrina Chiaretti, Fulvia Brugnolletti, Simona Tavolaro, Silvia Bonina, Francesca Paoloni, Marilisa Marinelli, Nancy Patten, Massimiliano Bonifacio, Maria Grazia Kropp, Simona Sica, Anna Guarini, and Robin Foà
  http://www.haematologica.org/content/98/5/e59

- Prevalence of a new auto-activating colony stimulating factor 3 receptor mutation (CSF3R-T595I) in acute myeloid leukemia and severe congenital neutropenia
  Renée Beckman, Marijke Valkhof, Paulette van Strien, Peter J.M. Valk, and Ivo P. Touw
  http://www.haematologica.org/content/98/5/e62

Continuing Medical Education

- Treatment of AL amyloidosis

- Survival and cure trends for young patients diagnosed with acute lymphoblastic leukemia

- Primary central nervous system lymphoma

JAK2 p.V617F allele burden as a predictive factor in myeloproliferative neoplasms

---

Treatments of AL amyloidosis

Survival and cure trends for young patients diagnosed with acute lymphoblastic leukemia

Primary central nervous system lymphoma

JAK2 p.V617F allele burden as a predictive factor in myeloproliferative neoplasms